Catalytic Enantioselective Synthesis of 4-Amino-5-aryltetrahydro-1H-benzo[c]azepines by an Aminoarylation Reaction

Sk Md Samim Akhtar; Saumen Hajra

doi:10.1055/a-1912-3285

Synlett, Table of Contents

Synlett 2023; 34(06): 645-650
DOI: 10.1055/a-1912-3285

cluster

Chemical Synthesis and Catalysis in India

Catalytic Enantioselective Synthesis of 4-Amino-5-aryltetrahydro-1H-benzo[c]azepines by an Aminoarylation Reaction

Sk Md Samim Akhtar

,

Saumen Hajra∗

Abstract

All articles of this category

Abstract

A one-pot asymmetric aminoarylation reaction has been executed for the synthesis of trans-4-amino-5-aryltetrahydrobenzo[c]azepines with excellent diastereo- and enantioselectivity (dr > 99: 1; ee ≤97%). The reaction progresses through aziridination of prochiral N-tosyl-N-cinnamylbenzylamines, followed by an intramolecular 7-endo-tet Friedel–Crafts cyclization of the tethered aziridines generated in situ, where the combination of Cu(OTf)₂ as a catalyst and PhINNs as a nitrene source was found to be effective. A chiral indenyl bis(oxazoline) was shown to be an efficient ligand for the catalytic enantioselective version of this one-pot transformation. This 7-endo-tet cyclization is contrary to the Baldwin cyclization rules.

Key words

tetrahydrobenzazepines - asymmetric catalysis - aminoarylation - aziridines - Friedel–Crafts reaction - endo-tet cyclization

Full Text

References

References and Notes
1 Present address: Department of Chemistry, Bidhan Chandra College, Asansol–713304, India

2a Xia W, Spector S, Hardy L, Zhao S, Saluk A, Alemane L, Spector NL. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 7494
2b Spector S, Spector NL. US 6277844, 2001
2c Al-Qawasmeh RA, Lee Y, Cao M.-Y, Gu X, Viau S, Lightfoot J, Wright JA, Young AH. Bioorg. Med. Chem. Lett. 2009; 19: 104
2d Keller L, Beaumont S, Liu J.-M, Thoret S, Bignon JS, Wdzieczak-Bakala J, Dauban P, Dodd RH. J. Med. Chem. 2008; 51: 3414
2e Pons V, Beaumont S, Tran Huu Dau ME, Iorga BI, Dodd RH. ACS Med. Chem. Lett. 2011; 2: 565
2f Zhan G, Zhou J, Liu R, Liu T, Guo G, Wang J, Xiang M, Xue Y, Luo Z, Zhang Y, Yao G. J. Nat. Prod. 2016; 79: 760
2g Scott LJ, Goa KL. Drugs 2000; 60: 1095
2h Grunewald GL, Dahanukar VH, Criscione KR. Bioorg. Med. Chem. 2001; 9: 1957
2i Grunewald GL, Caldwell TM, Li Q, Criscione KR. J. Med. Chem. 2001; 44: 2849
2j Bradshaw B, Evans P, Fletcher J, Lee AT. L, Mwashimba PG, Oehlrich D, Thomas EJ, Davies RH, Allen BC. P, Broadley KJ, Hamrouni A, Escargueil C. Org. Biomol. Chem. 2008; 6: 2138
2k Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Erhard KF, Heerding DA, Keenan RM, Kwon C, Manley PJ, Newlander KA, Ross ST, Samanen JM, Uzinskas IN, Venslavsky JW, Yuan C.-K, Haltiwanger RC, Gowen M, Hwang S.-M, James IE, Lark MW, Rieman DJ, Stroup GB, Azzarano LM, Salyers KL, Smith BR, Ward KW, Johanson KO, Huffman WF. J. Med. Chem. 2000; 43: 22
2l Clark MT, Chang J, Navran SS, Hoozor-Akbar Hoozor-Akbar, Mukhopadhyay A, Amin H, Feller DR, Miller DD. J. Med. Chem. 1986; 29: 181
2m Dalence-Guzman MF, Berglund M, Skogvall S, Sterner O. Bioorg. Med. Chem. 2008; 16: 2499
2n Berglund M, Dalence-Guzman MF, Skogvall S, Sterner O. Bioorg. Med. Chem. 2008; 16: 2513

3a Tabrizchi R. Curr. Opin. Invest. Drugs (BioMed Cent.) 2008; 9: 301
3b Schäfer S, Steioff K, Linz W, Bleich M, Busch AE, Löhn M. Eur. J. Pharmacol. 2004; 484: 361
3c Gross O, Koepke M.-L, Beirowski B, Schulze-Lohoff M, Segerer S, Weber M. Kidney Int. 2005; 68: 456

4a Burnier M. Curr. Opin. Invest. Drugs (BioMed Cent.) 2001; 10: 1957
4b Rossi GP. Cardiovasc. Drug Rev. 2003; 21: 51

5a Vandormael B, Fourla D.-D, Gramowski-Voß A, Kosson P, Weiss DG, Schröder OH.-U, Lipkowski A, Georgoussi Z, Tourwé D. J. Med. Chem. 2011; 54: 7848
5b Ballet S, Feytens D, Buysse K, Chung NN, Tumati S, Keresztes A, Van Duppen J, Lai J, Varga F, Porreca F, Schiller PW, Vanden Broeck J, Tourwé J. J. Med. Chem. 2011; 54: 2467 ; and references cited therein

6a Flynn GA, Giroux EL, Dage RC. J. Am. Chem. Soc. 1987; 109: 7914
6b Flynn GA, Beight DW, Huber EW, Bey P. Tetrahedron Lett. 1990; 31: 815
6c Warshawsky AM, Flynn GA, Koehl JR, Mehdi S, Vaz RJ. Bioorg. Med. Chem. Lett. 1996; 6: 957
6d Le Diguarher T, Ortuno J.-C, Shanks D, Guilbaud N, Pierré A, Raimbaud E, Fauchere J.-L, Hickman JA, Tucker GC, Casara PJ. Bioorg. Med. Chem. Lett. 2004; 14: 767

7a Lafemina RL, Young SD. GB 2271566 A, 1992
7b Johnson RE, Busacca CA. US 5098901, 1991
7c Sherlock MH. US 3225031, 1963
7d Sherlock MH. US 3242164, 1966
7e Masatoshi B, Kenji M, Yutaka B, Noriyuki I, Mikio H, Hajime F, Eiichi S. JP 5913761, 1984
7f Molino BF, Liu S, Sambandam A, Guzzo PR, Hu M, Zha C, Nacro K, Manning DD, Isherwood ML, Fleming KN, Cui W, Olson RE. WO2007011820, 2007
7g Gámez-Montaño R, Chávez MI, Roussi G, Cruz-Almanza R. Tetrahedron Lett. 2001; 42: 9

8a Kamimura A, Taguchi Y. Tetrahedron Lett. 2004; 45: 2335
8b Van den Eynde I, Van Rompaey K, Lazzaro F, Tourwé D. J. Comb. Chem. 2004; 6: 468
8c Vieira TO, Alper H. Org. Lett. 2008; 10: 485
8d Nandakumar A, Kiruthika SE, Naveen K, Perumal PT. Org. Biomol. Chem. 2014; 12: 876
8e Hu Y, Huang H. Org. Lett. 2017; 19: 5070
8f Pandey AK, Han SH, Mishra NK, Kang D, Lee SH, Chun R, Hong S, Park JS, Kim IS. ACS Catal. 2018; 8: 742

9a Baldwin JE. J. Chem. Soc., Chem. Commun. 1976; 732
9b Dumoulin D, Lebrun S, Couture A, Deniau E, Grandclaudon P. Tetrahedron: Asymmetry 2010; 21: 195
9c So M, Kotake T, Matsuura K, Inui M, Kamimura A. J. Org. Chem. 2012; 77: 4017
9d Allin SM, Towler JM. R, Elsegood MR. J, Saha B, Bulman Page PC. Synth. Commun. 2012; 42: 872
9e Quick MP, Fröhlich R, Schepmann D, Wünsch B. Org. Biomol. Chem. 2015; 13: 7265
9f Palillero-Cisneros A, Gordillo-Guerra PG, Aparicio-Solano DM, Gnecco D, Mendoza A, Juárez JR, Terán JL. Tetrahedron: Asymmetry 2015; 26: 95

10a Evans DA, Faul MM, Bilodeau MT. J. Org. Chem. 1991; 56: 6744
10b Evans DA, Faul MM, Bilodeau MT, Anderson BA, Barnes DM. J. Am. Chem. Soc. 1993; 115: 5328
10c Evans DA, Faul MM, Bilodeau MT. J. Am. Chem. Soc. 1994; 116: 2742

11a Hajra S, Maji B, Sinha D, Bar S. Tetrahedron Lett. 2008; 49: 4057
11b Hajra S, Maji B, Mal D. Adv. Synth. Catal. 2009; 351: 859
11c Hajra S, Bar S. Chem. Commun. 2011; 47: 3981
11d Hajra S, Bar S. Tetrahedron: Asymmetry 2011; 22: 775
11e Hajra S, Bar S. Tetrahedron: Asymmetry 2012; 23: 151
11f Hajra S, Sinha D. J. Org. Chem. 2011; 76: 7334
11g Hajra S, Akhtar SkM. S, Aziz SkM. Chem. Commun. 2014; 50: 6913
11h Akhta SkM. S, Bar S, Hajra S. Tetrahedron 2022; 103: 132257

For reviews, see:

12a Hu XE. Tetrahedron 2004; 60: 2701
12b Singh GS, Sudheesh S, Keroletswe N. ARKIVOC 2018; (i): 50
12c Talukdar R, Saha A, Ghorai MK. Isr. J. Chem. 2016; 56: 445

For selected examples see:

12d Bhattacharyya A, Shahi CK, Pradhan S, Ghorai MK. Org. Lett. 2018; 20: 2925
12e Pradhan S, Chauhan N, Shahi CK, Bhattacharyya A, Ghorai MK. Org. Lett. 2020; 22: 7903
12f Tarannum S, Sk S, Das S, Wani IA, Ghorai MK. J. Org. Chem. 2020; 85: 367

13 4-Amino-5-aryltetrahydro-2-benzazepines 3b–j; General Procedure A two-necked, 25 mL, round-bottomed flask was charged with the Box ligand (1R,2S)-L6 (0.011 g, 0.03 mmol, 0.12 equiv) and Cu(OTf)₂ (0.009 g, 0.025 mmol, 0.1 equiv). Anhyd CH₂Cl₂ (1.2 mL) was added by syringe, and the resulting mixture was stirred for 30 min at rt. To this solution were added substrate 1 (0.467 g, 1.23 mmol, 5.0 equiv) in CH₂Cl₂ (1.2 mL), PhINNs (0.1 g, 0.24 mmol, 1.0 equiv), and powered 4Å MS (0.2 g) and the mixture stirred at rt under argon. As soon as all the nitrenoid reagents were dissolved, additional Cu(OTf)₂ (0.007 g, 0.01 mmol, 0.1 equiv) was added to the reaction medium, which was then stirred at 35 °C under argon. The reaction, which was completed within 1 h, was quenched by dilution with EtOAc (10 mL). The mixture was then filtered through a short plug of silica gel that was washed with additional EtOAc (10 mL). The filtrate was concentrated by rotary evaporation under reduced pressure to give a crude mass that was purified by flash column chromatography (silica gel, EtOAc–hexane). N-{(4S,5R)-5-Phenyl-2-tosyl-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl}-4-nitrobenzenesulfonamide (3b) White solid; yield: 91% (96% ee); mp 164–166 °C; [α]_D ²⁸ −137 (c 0.30, CH₂Cl₂). HPLC [Daicel Chiralpak IA-3, hexane–EtOAc (60:40), 1.0 mL/min, λ = 254 nm]: t _major = 6.1 min, t _minor = 7.2 min. ¹H NMR (400 MHz, CDCl₃): δ = 8.12 (d, J = 9.2 Hz, 2 H), 7.62 (d, J = 8.0 Hz, 2 H), 7.52 (d, J = 8.8 Hz, 2 H), 7.34 (d, J = 8.0 Hz, 2 H), 7.27–7.25 (m, 3 H), 7.19–7.17 (m, 3 H), 7.10 (d, J = 6.8 Hz, 4 H), 5.03 (d, J = 9.2 Hz, 1 H), 4.99–4.96 (m, 1 H), 4.34 (d, J = 9.2 Hz, 1 H), 3.86 (d, J = 10.8 Hz, 1 H), 3.24 (dd, J = 10.0, 2.0 Hz, 1 H), 3.18–3.14 (m, 1 H), 2.49 (s, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ = 150.0, 144.6, 143.8, 140.5, 139.5, 132.9, 129.9, 128.9, 128.6, 128.5, 128.4, 128.3, 128.2, 127.7, 127.4, 127.1, 124.2, 62.9, 62.2, 53.8, 49.4, 21.6. DEPT-135 NMR (100 MHz, CDCl₃): δ = 130.4, 129.4, 129.2, 129.1, 129.0, 128.7, 128.6, 128.1, 127.9, 127.5, 124.6, 63.3, 62.7, 54.2, 49.9, 22.0. ESI-MS: m/z [M + Na]⁺ calcd for C₂₉H₂₇N₃NaO₆S₂: 600.1239; found: 600.1238.

Supplementary Material

Supporting Information